Clinical Trials Browser

Lymphoma, T-Cell, Cutaneous × durvalumab × 1 year × Clear all

NCT03011814 2025-09-18

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Phase 1/2 Active not recruiting

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous